New York State Common Retirement Fund Decreases Stake in Xencor Inc (XNCR)

New York State Common Retirement Fund lowered its stake in shares of Xencor Inc (NASDAQ:XNCR) by 31.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,148 shares of the biopharmaceutical company’s stock after selling 23,075 shares during the quarter. New York State Common Retirement Fund owned about 0.11% of Xencor worth $1,172,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. SG Americas Securities LLC grew its position in Xencor by 62.6% during the second quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 3,252 shares in the last quarter. Legal & General Group Plc grew its position in Xencor by 4.5% during the second quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 385 shares in the last quarter. Principal Financial Group Inc. acquired a new stake in Xencor during the third quarter worth approximately $201,000. Citadel Advisors LLC acquired a new stake in Xencor during the second quarter worth approximately $224,000. Finally, Airain ltd grew its position in Xencor by 49.9% during the second quarter. Airain ltd now owns 13,360 shares of the biopharmaceutical company’s stock worth $282,000 after buying an additional 4,447 shares in the last quarter. 77.50% of the stock is currently owned by institutional investors and hedge funds.

In other news, major shareholder John S. Stafford III purchased 24,653 shares of the company’s stock in a transaction dated Wednesday, October 25th. The stock was bought at an average cost of $20.01 per share, for a total transaction of $493,306.53. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder John S. Stafford III purchased 6,215 shares of the company’s stock in a transaction dated Tuesday, December 12th. The stock was purchased at an average price of $20.72 per share, with a total value of $128,774.80. The disclosure for this purchase can be found here. Insiders have acquired 278,535 shares of company stock valued at $5,526,936 over the last 90 days. Corporate insiders own 4.03% of the company’s stock.

A number of equities research analysts recently issued reports on the company. BidaskClub raised Xencor from a “strong sell” rating to a “sell” rating in a research report on Thursday, December 7th. Zacks Investment Research upgraded Xencor from a “sell” rating to a “hold” rating in a research note on Wednesday, November 22nd. Piper Jaffray Companies restated a “buy” rating and set a $35.00 target price on shares of Xencor in a research note on Sunday, November 12th. ValuEngine cut Xencor from a “hold” rating to a “sell” rating in a research note on Monday, October 23rd. Finally, Canaccord Genuity set a $36.00 target price on Xencor and gave the stock a “buy” rating in a research note on Monday, October 23rd. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company’s stock. Xencor currently has a consensus rating of “Hold” and an average target price of $30.80.

Shares of Xencor Inc (NASDAQ:XNCR) opened at $23.16 on Friday. Xencor Inc has a 12 month low of $18.55 and a 12 month high of $28.64. The firm has a market capitalization of $1,090.00, a price-to-earnings ratio of -22.93 and a beta of 2.09.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/3126419/new-york-state-common-retirement-fund-decreases-stake-in-xencor-inc-xncr.html.

Xencor Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor Inc (NASDAQ:XNCR).

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.